1290541-46-6 Usage
Description
3-(Phenylmethyl)-2-[(1E)-2-(3-pyridinyl)ethenyl]-4(3H)-quinazolinone is a cell-permeable pyridinylvinyl-quinazolinone compound that has been shown to specifically inhibit human RAD51, a protein involved in DNA repair. 3-(Phenylmethyl)-2-[(1E)-2-(3-pyridinyl)ethenyl]-4(3H)-quinazolinone directly interacts with RAD51, disrupting its binding to DNA and nucleoprotein filament formation. It is characterized by its ability to block double-strand break-induced homologous recombination and enhance the sensitivity of cells to certain chemotherapeutic agents.
Uses
Used in Cancer Therapy:
3-(Phenylmethyl)-2-[(1E)-2-(3-pyridinyl)ethenyl]-4(3H)-quinazolinone is used as a RAD51 inhibitor for improving the efficacy of chemotherapy. By inhibiting RAD51, this compound may enhance the sensitivity of cancer cells to chemotherapeutic agents such as Cisplatin and Mitomycin C, potentially leading to more effective treatment outcomes.
Used in Porcine Embryo Research:
In the field of porcine embryo research, 3-(Phenylmethyl)-2-[(1E)-2-(3-pyridinyl)ethenyl]-4(3H)-quinazolinone is used as a RAD51 inhibitor to test its effect on the polar body extrusion (PBE) rate in porcine oocytes. This application aims to understand the role of RAD51 inhibition in porcine embryos and its potential implications for embryo development.
Used in Induced Pluripotent Stem Cells (iPSCs) Research:
3-(Phenylmethyl)-2-[(1E)-2-(3-pyridinyl)ethenyl]-4(3H)-quinazolinone is also used as a RAD51 inhibitor in the context of induced pluripotent stem cells (iPSCs). It is employed to test its effect on targeted nucleotide substitution (TNS) in iPSCs, which could provide insights into the role of RAD51 in genomic stability and the potential applications of this compound in stem cell research and therapy.
Biochem/physiol Actions
B02 (3-(Phenylmethyl)-2-[(1E)-2-(3-pyridinyl)ethenyl]-4(3H)-quinazolinone), a pyridinylvinyl-quinazolinone compound is cell-permeable. B02 inhibits human RAD51 recombinase and subsequent nucleofilaments formation. It halts homologous recombination (HR) repair events in cancer cells. B02 favors apoptosis in multiple myeloma and is crucial for sensitizing them to doxorubicin.
Check Digit Verification of cas no
The CAS Registry Mumber 1290541-46-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,9,0,5,4 and 1 respectively; the second part has 2 digits, 4 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1290541-46:
(9*1)+(8*2)+(7*9)+(6*0)+(5*5)+(4*4)+(3*1)+(2*4)+(1*6)=146
146 % 10 = 6
So 1290541-46-6 is a valid CAS Registry Number.
1290541-46-6Relevant articles and documents
Quinazolinone derivatives as inhibitors of homologous recombinase RAD51
Ward, Ambber,Dong, Lilong,Harris, Jonathan M.,Khanna, Kum Kum,Al-Ejeh, Fares,Fairlie, David P.,Wiegmans, Adrian P.,Liu, Ligong
supporting information, p. 3096 - 3100 (2017/06/13)
RAD51 is a vital component of the homologous recombination DNA repair pathway and is overexpressed in drug-resistant cancers, including aggressive triple negative breast cancer (TNBC). A proposed strategy for improving therapeutic outcomes for patients is through small molecule inhibition of RAD51, thereby sensitizing tumor cells to DNA damaging irradiation and/or chemotherapy. Here we report structure-activity relationships for a library of quinazolinone derivatives. A novel RAD51 inhibitor (17) displays up to 15-fold enhanced inhibition of cell growth in a panel of TNBC cell lines compared to compound B02, and approximately 2-fold increased inhibition of irradiation-induced RAD51 foci formation. Additionally, compound 17 significantly inhibits TNBC cell sensitivity to DNA damage, implying a potentially targeted therapy for cancer treatment.
